Dry Eye | Treatment Algorithms: Claims Data Analysis | US | 2021

Few drugs are approved in the United States to treat dry eye disease (DED). AbbVie’s blockbuster Restasis was the only therapy approved for this indication for more than a decade until the launch of Novartis’s Xiidra in 2016, the newer Restasis MultiDose formulation in 2017, and Sun Ophthalmics’ Cequa in 2019. In addition to these approved drugs, pharmacotherapies such as topical corticosteroids are commonly prescribed to treat DED. The claims analysis provides manufacturers of current treatments, as well as those developing novel agents for DED, with real-world insight regarding recent trends in the use of DED drugs.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed DED patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DED patients?
  • How have Restasis, Restasis MultiDose, Xiidra, and Cequa been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of DED patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of DED patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: AbbVie, Novartis, Sun Ophthalmics

Key drugs: Restasis, Restasis MultiDose, Xiidra, Cequa, corticosteroids (ophthalmic), antibiotics (oral and ophthalmic)

Login to access report